Eli Lilly and Company Announces Positive Topline Results from the Phase 3 LIBRETTO-432 Clinical Trial of Retevmo
Eli Lilly and Company announced positive topline results from the Phase 3 LIBRETTO-432 clinical trial of Retevmo as adjuvant therapy versus placebo. The study met its primary endpoint, demonstrating...